CARB-X partners with Macrolide Pharmaceuticals to develop novel macrolide antibiotics with Gram-negative activity
Summary
The platform is a groundbreaking technological advance that holds the foundational key to discover and create new macrolides from basic chemical building blocks that transform this class from its traditional Gram-positive spectrum to include multi-drug resistant (MDR) Gram-negative pathogens. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK) HHS is the principal federal agency for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. Within ASPR, BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, innovation, acquisition, and manufacturing of vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health emergency threats. NIAID conducts and supports research – at NIH, throughout the United States, and worldwide – to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. By maintaining its focus on entrepreneurship, education and career development programs, CLSI supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem.